We are live on
!
Find out more
O
OrbiMed Portfolio holdings
AUM
$4.59B
1-Year Est. Return
125.28%
This Fund
S&P 500
This Quarter
Est. Return
+7.88%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$3.98B
AUM Growth
-$187M
(-4.5%)
Cap. Flow
-$236M
Cap. Flow
% of AUM
-5.94%
Top 10 Holdings %
Top 10 Hldgs %
49.18%
Holding
122
New
13
Increased
19
Reduced
24
Closed
22
Top Buys
| 1 |
CAI
Caris Life Sciences
CAI
|
+$81.8M |
| 2 |
UnitedHealth
UNH
|
+$51.6M |
| 3 |
Roivant Sciences
ROIV
|
+$30.1M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
+$23.2M |
| 5 |
JBIO
Jade Biosciences
JBIO
|
+$18.1M |
Top Sells
| 1 |
Pfizer
PFE
|
+$97.6M |
| 2 |
Ionis Pharmaceuticals
IONS
|
+$76.6M |
| 3 |
Neurocrine Biosciences
NBIX
|
+$56.9M |
| 4 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$41.9M |
| 5 |
Thermo Fisher Scientific
TMO
|
+$34.5M |
Sector Composition
| 1 | Healthcare | 99.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MBX
26
MBX Biosciences
MBX
$2.86B
| $45.7M | 1.15% |
4,002,887
| – | – |
|
27
Axsome Therapeutics
AXSM
$12.2B
| $44.7M | 1.12% |
427,900
+41,200
| +11% | +$4.36M |
|
28
Compass Therapeutics
CMPX
$391M
| $39.6M | 1% |
15,219,994
-7,142,856
| -32% | -$14.7M |
|
29
Cytokinetics
CYTK
$11.2B
| $35.6M | 0.89% |
1,077,000
-432,205
| -29% | -$15M |
|
30
Crinetics Pharmaceuticals
CRNX
$8.88B
| $33M | 0.83% |
1,149,000
+150,000
| +15% | +$4.63M |
|
|
EXAS
31
DELISTED
Exact Sciences
EXAS
| $32.3M | 0.81% |
607,316
-72,500
| -11% | -$3.68M |
|
|
THRD
32
DELISTED
Third Harmonic Bio
THRD
| $31.4M | 0.79% |
5,779,071
| – | – |
|
|
33
Roivant Sciences
ROIV
$25.2B
| $31.3M | 0.79% |
+2,779,427
| New | +$30.1M |
|
34
Xenon Pharmaceuticals
XENE
$6.54B
| $29.7M | 0.75% |
947,877
| – | – |
|
35
Neuropace
NPCE
$552M
| $29.1M | 0.73% |
2,614,184
-792,151
| -23% | -$9.9M |
|
36
Corvus Pharmaceuticals
CRVS
$1.26B
| $28.7M | 0.72% |
7,165,006
+221,352
| +3% | +$805K |
|
|
TERN
37
DELISTED
Terns Pharmaceuticals
TERN
| $28.2M | 0.71% |
7,562,971
| – | – |
|
38
Janux Therapeutics
JANX
$971M
| $28M | 0.7% |
1,210,300
+451,734
| +60% | +$11.9M |
|
|
APLS
39
DELISTED
Apellis Pharmaceuticals
APLS
| $25.7M | 0.65% |
1,482,300
+50,000
| +3% | +$926K |
|
40
Structure Therapeutics
GPCR
$3.5B
| $24.9M | 0.63% |
1,199,300
+547,272
| +84% | +$12M |
|
|
SCPH
41
DELISTED
scPharmaceuticals
SCPH
| $23.1M | 0.58% |
6,059,528
| – | – |
|
42
CytomX Therapeutics
CTMX
$797M
| $19.2M | 0.48% |
+8,461,500
| New | +$13.6M |
|
|
43
Thermo Fisher Scientific
TMO
$200B
| $18.9M | 0.47% |
46,500
-82,500
| -64% | -$34.5M |
|
44
Agios Pharmaceuticals
AGIO
$2.38B
| $18.6M | 0.47% |
557,900
+232,400
| +71% | +$7.04M |
|
45
Trevi Therapeutics
TRVI
$2.56B
| $18.1M | 0.46% |
3,308,400
+2,188,400
| +195% | +$13.6M |
|
46
ADC Therapeutics
ADCT
$160M
| $15.8M | 0.4% |
5,907,351
-61,100
| -1% | -$129K |
|
47
Rhythm Pharmaceuticals
RYTM
$7.52B
| $15.7M | 0.39% |
248,512
-131,488
| -35% | -$8.05M |
|
48
Forte Biosciences
FBRX
$911M
| $15.5M | 0.39% |
1,196,955
+603,867
| +102% | +$5.2M |
|
49
Cullinan Oncology
CGEM
$1.09B
| $14.5M | 0.36% |
1,923,855
| – | – |
|
50
Keros Therapeutics
KROS
$213M
| $13.6M | 0.34% |
1,018,734
| – | – |
|
Similar funds
CGI
LNWTC
SCM
AG
SCM
SV
ANTB
ECM